基础医学与临床 ›› 2023, Vol. 43 ›› Issue (10): 1567-1571.doi: 10.16352/j.issn.1001-6325.2023.10.1567

• 临床研究 • 上一篇    下一篇

纳布啡与舒芬太尼预防输尿管镜碎石术后导尿管相关膀胱刺激征的比较

杨旺燕1, 李雷1, 任海强1, 杜鹃1, 闫莉2, 杨彦伟1*   

  1. 1.清华大学附属垂杨柳医院 麻醉科,北京 100022;
    2.中国医学科学院基础医学研究所 北京协和医学院基础学院 病理生理学系,北京 100005
  • 收稿日期:2023-02-22 修回日期:2023-04-26 出版日期:2023-10-05 发布日期:2023-10-05
  • 通讯作者: *yyw1980pg@sina.com
  • 基金资助:
    白求恩公益基金会恩泽疼痛管理医学研究项目(ezmr2022-062)

Comparison of nalbuphine and sufentanil in preventing of catheter- related bladder discomfort after transurethral ureteroscopic lithotripsy

YANG Wangyan1, LI Lei1, REN Haiqiang1, DU Juan1, YAN Li2, YANG Yanwei1*   

  1. 1. Department of Anesthesiology, Chuiyangliu Hospital Affiliated to Tsinghua University, Beijing 100022;
    2. Department of Pathophysiology,Institute of Basic Medical Sciences CAMS,School of Basic Medicine PUMC, Beijing 100005, China
  • Received:2023-02-22 Revised:2023-04-26 Online:2023-10-05 Published:2023-10-05
  • Contact: *yyw1980pg@sina.com

摘要: 目的 对比纳布啡与舒芬太尼预防全身麻醉下经尿道输尿管镜碎石术后男性患者导尿管相关膀胱刺激征(CRBD)的效果。方法 选择择期全麻下行经尿道输尿管镜碎石术的男性患者158例,年龄25~65岁,美国麻醉医师学会(ASA)Ⅰ~ Ⅲ级。采用随机数字表法将患者分为纳布啡组(N组)、舒芬太尼组(S组)两组,每组79例。N组全麻诱导给予纳布啡0.2 mg/kg,S组诱导给予舒芬太尼0.2 μg/kg,其余麻醉诱导药物及维持方法相同。分别记录全麻苏醒时(T0)及苏醒后10 min (T1)、20 min (T2)、30 min (T3)、1 h (T4) 5个时点两组患者的 CRBD发生情况及严重程度、Ramsay镇静评分、呼吸抑制及恶心呕吐等不良反应。 结果 两组T3,T4时点CRBD发生率显著高于T0时点(P<0.05);与S组相比,N组在T3时点CRBD发生率及重度CRBD的发生率均显著降低(P<0.05);N组T3时点Ramsay镇静评分显著高于S组(P<0.05);两组术后不良反应差异无统计学意义。结论 对于经尿道输尿管镜碎石的男性患者,全麻诱导时给予纳布啡更有助于降低术后苏醒期间CRBD的发生率及严重程度,且不良反应较少。

关键词: 纳布啡, 舒芬太尼, 输尿管镜碎石术, 导尿管相关膀胱刺激征

Abstract: Objective To compare the analgesic effect of nalbuphine and sufentanil in preventing catheter-related bladder discomfort (CRBD) after transurethral ureteroscopic lithotripsy. Methods A total of 158 male patients undergoing transurethral ureteroscopic lithotripsy with general anesthesia, classified with American Society of Anesthesiologists (ASA) physical status as grade Ⅰ to Ⅲ, aged from 25 to 65 years old, were selected as subjects. Patients were randomly divided into two groups with 79 in each group: nalbuphine group (group N) and sufentanil group (group S). Patients in group N were treated with 0.2 mg/kg nalbuphine, while those in group S were treated with 0.2 μg/kg sufentanil at the induction of general anesthesia. The other procedures and drugs for anesthesia induction and maintenance were same in two groups. The frequency and severity of CRBD postoperatively, Ramsay sedation score, respiratory depression and postoperative nausea and vomiting were examined at 0 min (T0), 10 min(T1), 20 min (T2), 30 min (T3), and 1 h (T4) after recovery from general anesthesia. Results The incidence of CRBD at T3 and T4 were significantly higher than that at T0 in two groups. Compared with group S, the incidence and severity of CRBD were significantly lower in group N at T3(P<0.05), and the Ramsay sedation score was higher in group N at T3 (P<0.05). However, the incidence of postoperative adverse reactions was not significantly different between the two groups. Conclusions Nalbuphine used for induction of general anesthesia, can effectively reduce the incidence and severity of CRBD in male patients after transurethral ureteroscopic lithotripsy during anesthesia recovery period with fewer adverse reactions.

Key words: nalbuphine, ureteroscopic lithotripsy, catheter-related bladder discomfort

中图分类号: